Lung Tumor Board - 8/21/2025

Thursday, August 21, 2025, 8:00 AM - 9:00 AM

Provided by Rutgers Cancer Institute

Objective(s): 1 Define the current Tumor %, Node (N), and Metastasis (M) staging of lung cancer and other thoracic malignancies and their relationship to treatment approaches and survival outcomes. 2 Correlate and integrate the clinical oncologic diagnosis with the pathologic, radiologic, and surgical findings of the cases presented. 3 Analyze oncological decision making processes and judgment to identify approaches to patient management and care, including cancer treatments (and management of toxicities), and supportive care. 4 Identify alternative courses of action and new knowledge, including cancer clinical trials presented to improve specific patient outcomes and quality of life 5 Evaluate new technology, molecular targets, and therapies in oncological care and recommend adoption of best practices.
Location:

Faculty Disclosures:
Judith K Amorosa, MD (Nothing to disclose - 04/29/2025)
Allan Louie Cruz, MD (Nothing to disclose - 06/25/2025)
Missak Haigentz, MD (Member, Advisory Board-AstraZeneca (Relationship has ended)|Member, Advisory Board-Janssen Pharmaceuticals (Relationship has ended)|Member, Advisory Board-Boehringer Ingelheim Pharmaceuticals (Relationship has ended) - 07/23/2025)
Imraan Jan, DO (Nothing to disclose - 07/17/2025)
Salma K. Jabbour, MD (Consultant-Merck|Grant/research support-Merck|Grant/research support-Beigene|Consultant-AstraZeneca|Consultant-Radialogica - 07/28/2025)
Ioannis Kontopidis, MD (Nothing to disclose - 04/28/2025)
John E. Langenfeld, MD (Nothing to disclose - 04/24/2025)
Kevin Law, MD (Nothing to disclose - 05/10/2025)
Benjamin Medina, MD (Nothing to disclose - 04/24/2025)
Sivraj Muralikrishnan, MD (Nothing to disclose - 07/15/2025)
Malini Patel, MD (Nothing to disclose - 05/19/2025)
Karleung Siu, MD (Nothing to disclose - 07/04/2025)
Arunabh Sekhri, MD (Nothing to disclose - 05/01/2025)
Download Handout

1. Define the current Tumor %, Node (N), and Metastasis (M) staging of lung cancer and other thoracic malignancies and their relationship to treatment approaches and survival outcomes.
2. Correlate and integrate the clinical oncologic diagnosis with the pathologic, radiologic, and surgical findings of the cases presented.
3. Analyze oncological decision making processes and judgment to identify approaches to patient management and care, including cancer treatments (and management of toxicities), and supportive care.
4. Identify alternative courses of action and new knowledge, including cancer clinical trials presented to improve specific patient outcomes and quality of life
5. Evaluate new technology, molecular targets, and therapies in oncological care and recommend adoption of best practices.

In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Contact: Patricia Walker - [email protected]; Estefany Torres - [email protected]; Lamika Young - [email protected]

AMA PRA Category 1 Credits™ (1.00 hours), ACPE Credits (1.00 hours), ANCC Contact Hours (1.00 hours), Non-Physician Attendance (1.00 hours)

Mitigation of Relevant Financial Relationships

Date	Empty Column	Title
		No activities are currently published for this month.
No upcoming dates have been setup.